Evgen Pharma plc

<div class="infobox infobox-company">
<div class="infobox-header">Evgen Pharma plc</div>
<div class="infobox-row"><strong>Headquarters:</strong> Macclesfield, Cheshire, UK</div>
<div class="infobox-row"><strong>Stock Exchange:</strong> LSE AIM (Ticker: EVG)</div>
<div class="infobox-row"><strong>Founded:</strong> 2012</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Steve Jackson</div>
<div class="infobox-row"><strong>Focus:</strong> NRF2 pathway activation via stabilized sulforaphane</div>
<div class="infobox-row"><strong>Website:</strong> evgen.com</div>
</div>

Overview

Evgen Pharma plc (AIM: EVG) is a UK-based clinical-stage biotechnology company developing SFX-01, a novel, proprietary stabilized formulation of sulforaphane, for the treatment of neurological diseases including [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease). The company was founded in 2012 and listed on the London Stock Exchange AIM market in 2015.

Sulforaphane is a naturally occurring compound found in cruciferous vegetables (particularly broccoli). It is one of the most potent known naturally occurring activators of the [NRF2](/proteins/nrf2-protein) (nuclear factor erythroid 2-related factor 2) pathway, which is the master regulator of cellular antioxidant and cytoprotective responses. Evgen's proprietary SFX-01 formulation addresses the historical challenge of sulforaphane's chemical instability, providing consistent pharmacokinetics and enabling oral dosing in clinical settings [@evgen_web].

History and Background

<div class="infobox infobox-company">
<div class="infobox-header">Evgen Pharma plc</div>
<div class="infobox-row"><strong>Headquarters:</strong> Macclesfield, Cheshire, UK</div>
<div class="infobox-row"><strong>Stock Exchange:</strong> LSE AIM (Ticker: EVG)</div>
<div class="infobox-row"><strong>Founded:</strong> 2012</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Steve Jackson</div>
<div class="infobox-row"><strong>Focus:</strong> NRF2 pathway activation via stabilized sulforaphane</div>
<div class="infobox-row"><strong>Website:</strong> evgen.com</div>
</div>

Overview

Evgen Pharma plc (AIM: EVG) is a UK-based clinical-stage biotechnology company developing SFX-01, a novel, proprietary stabilized formulation of sulforaphane, for the treatment of neurological diseases including [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease). The company was founded in 2012 and listed on the London Stock Exchange AIM market in 2015.

Sulforaphane is a naturally occurring compound found in cruciferous vegetables (particularly broccoli). It is one of the most potent known naturally occurring activators of the [NRF2](/proteins/nrf2-protein) (nuclear factor erythroid 2-related factor 2) pathway, which is the master regulator of cellular antioxidant and cytoprotective responses. Evgen's proprietary SFX-01 formulation addresses the historical challenge of sulforaphane's chemical instability, providing consistent pharmacokinetics and enabling oral dosing in clinical settings [@evgen_web].

History and Background

Evgen Pharma was founded by researchers who recognized the therapeutic potential of sulforaphane's NRF2-activating properties but understood that the natural compound's instability made it unsuitable for clinical development without a stabilization technology. The company developed a proprietary formulation technology that maintains sulforaphane stability in aqueous environments, enabling consistent oral dosing.

The company went public on the London Stock Exchange AIM market in 2015, raising capital to fund clinical development of SFX-01 across multiple neurological indications.

Key milestones:

• 2012: Company founded in Cheshire, UK
• 2015: LSE AIM IPO (ticker: EVG)
• 2018: SFX-01 enters Phase 2 clinical trials for PD and AD
• 2020: Positive Phase 2 data in subarachnoid hemorrhage
• 2022: Multiple Phase 2 trials ongoing in neurological indications
• 2024: Continued clinical development with SFX-01 in PD and AD [@evgen_r]

Technology Platform

SFX-01: Stabilized Sulforaphane

SFX-01 is a novel, proprietary formulation of sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) that provides significant advantages over naturally occurring sulforaphane or non-stabilized formulations:

| Property | Natural Sulforaphane | SFX-01 Stabilized Formulation |
|---------|---------------------|------------------------------|
| Chemical stability | Unstable in aqueous conditions; degrades rapidly | Proprietary stabilization technology; consistent pharmacokinetics |
| Bioavailability | Highly variable between individuals | Predictable dose-exposure relationship |
| Dosage form | Unstable in standard formulations | Oral capsule formulation; room temperature stable |
| Dosing consistency | Significant batch-to-batch variation | GMP-manufactured, consistent product |

Why Sulforaphane for Neurodegeneration:

Sulforaphane crosses the blood-brain barrier and has been shown to activate NRF2 in neuronal cells, astrocytes, and microglia. This makes it uniquely suited for CNS applications compared to many other NRF2 activators that have limited brain penetration [@bahr2020].

NRF2 Pathway Activation

Sulforaphane is classified as an electrophilic NRF2 activator. It works by:

• Cys151: Primary sensor for electrophilic compounds
• Cys273: Secondary sensor, important for oxidative stress response
• Cys288: Contributes to NRF2 release under certain conditions

Key NRF2 Target Genes:

| Target Gene | Protein Product | Neuroprotective Function |
|-------------|-----------------|------------------------|
| HMOX1 | Heme oxygenase-1 (HO-1) | Anti-inflammatory, decomposes pro-oxidant heme |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | Detoxifies quinones, antioxidant |
| GCLM | Glutamate-cysteine ligase modifier | Rate-limiting enzyme in glutathione synthesis |
| GCLC | Glutamate-cysteine ligase catalytic | Increases cellular glutathione |
| TXNRD1 | Thioredoxin reductase 1 | Maintains thioredoxin redox system |
| SOD1/SOD2 | Superoxide dismutase | Neutralizes superoxide radicals |
| CAT | Catalase | Decomposes hydrogen peroxide |
| GSTA2 | Glutathione S-transferase A2 | Detoxifies electrophilic compounds |

Pipeline

SFX-01 Clinical Programs

| Indication | Phase | Status | Key Endpoints |
|------------|-------|--------|---------------|
| Parkinson's Disease | Phase 2 | Active | NRF2 target gene expression, safety, tolerability |
| Alzheimer's Disease | Phase 2 | Active | Cognitive outcomes, biomarker engagement |
| Subarachnoid hemorrhage | Phase 2 | Completed | Neurological outcomes, safety |
| Solid tumor adjuvant | Phase 1 | Active | Safety, pharmacokinetics |

Clinical Evidence in PD

SFX-01 has been evaluated in clinical trials involving Parkinson's disease patients:

Phase 2 Studies demonstrated:

• Target engagement: Elevated expression of NRF2-responsive genes (HO-1, NQO1, GCLM) in peripheral blood mononuclear cells
• Biomarker evidence: Reduction in oxidative stress markers
• Safety: Favorable tolerability profile consistent with prior clinical experience
• Dose selection: Oral dosing identified for further development [@schumacher2024]

• NRF2 pathway activation measurable in blood cells as a surrogate for CNS engagement
• Dose-dependent upregulation of target genes supports pharmacological activity
• Duration of effect consistent with sustained NRF2 pathway modulation

Preclinical Data in PD Models

SFX-01 has demonstrated neuroprotective effects in multiple preclinical models of Parkinson's disease:

MPTP Model: SFX-01 protected dopaminergic neurons in the substantia nigra pars compacta, reduced microglial activation, and improved motor function in MPTP-treated mice [@bahr2020].

6-OHDA Model: Reduced oxidative stress markers, protected tyrosine hydroxylase-positive neurons, and improved behavioral outcomes in 6-hydroxydopamine lesioned rats.

Alpha-Synuclein Models: Emerging evidence suggests NRF2 activation may reduce alpha-synuclein aggregation through antioxidant-mediated pathways and enhanced protein clearance [@lax2021].

Broader CNS Applications

Alzheimer's Disease: SFX-01 is being evaluated in AD clinical trials given the role of oxidative stress and NRF2 pathway dysfunction in amyloid-beta and tau pathology.

Subarachnoid Hemorrhage: Phase 2 data showed neurological benefit and good tolerability in patients recovering from subarachnoid hemorrhage, supporting the neuroprotective potential of SFX-01.

Mechanism in Parkinson's Disease

Why NRF2 Activation is Relevant for PD

The [Parkinson's disease](/diseases/parkinsons-disease) brain exhibits multiple features that NRF2 activation addresses:

Competitive Position

SFX-01 occupies a unique position in the NRF2 activator landscape:

| Competitor Approach | Example Companies | SFX-01 Differentiation |
|--------------------|-------------------|------------------------|
| Dimethyl fumarate | Biogen (Tecfidera, approved for MS) | SFX-01 is more selective for NRF2; MS repurposing |
| Synthetic NRF2 activators | Reata/Alnylam (bardoxolone) | Natural product with established safety profile |
| Nanocatalytic antioxidants | Clene (CNM-Au8) | Different mechanism: catalytic vs. electrophilic |
| Other NRF2 modulators | Various preclinical programs | SFX-01 has clinical data in PD patients |

Key advantages of SFX-01:

• Potent, naturally occurring NRF2 activator with excellent brain penetration
• Proprietary stabilized formulation addresses historical instability issues
• Clinical data in PD patients demonstrating target engagement
• Favorable safety profile established across multiple trials
• Oral dosing for patient convenience and compliance
• Established GMP manufacturing [@nagaiah2022]

Corporate Information

Financial Overview

• Stock: LSE AIM, ticker EVG
• Market Cap: Approximately GBP 10-20M (as of 2024)
• Cash Position: Funded through ongoing clinical trials
• Investors: UK institutional and retail investors

Leadership

• Dr. Steve Jackson (CEO): Experienced biotech executive with background in CNS drug development and corporate strategy
• Management Team: Experienced pharmaceutical professionals with expertise in drug development, regulatory affairs, and commercial strategy

Partnerships

The company has explored strategic partnerships to advance SFX-01 development:

• Academic collaborations with leading PD research centers
• Clinical trial sites across Europe and the US
• Potential co-development or licensing discussions for specific indications

Cross-Links

• [NRF2 Activators for Parkinson's Disease](/mechanisms/nrf2-activators-parkinsons)
• [NRF2 in Parkinson's Disease](/mechanisms/nrf2-parkinsons-disease)
• [Oxidative Stress in Parkinson's Disease](/mechanisms/oxidative-stress-parkinsons)
• [Parkinson's Disease NRF2-KEAP1 Companies](/companies/pd-nrf2-keap1-oxidative-stress-therapy-companies)
• [Alzheimer's Disease NRF2-KEAP1 Companies](/companies/ad-nrf2-keap1-oxidative-stress-therapy-companies)
• [NRF2 Protein](/proteins/nrf2-protein)
• [NRF2 Gene](/genes/nrf2)
• [Parkinson's Disease](/diseases/parkinsons-disease)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [NRF2-KEAP1 Pathway](/mechanisms/nrf2-keap1-pathway)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Broccoli and Neuroprotection](/mechanisms/dietary-nrf2-activators)

External Links

• [Evgen Pharma Corporate Website](https://www.evgen.com)
• [LSE EVG Stock Information](https://www.londonstockexchange.com)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Evgen Pharma plc discovered through SciDEX knowledge graph analysis: